1
|
Avila C, Angulo-Preckler C. Bioactive Compounds from Marine Heterobranchs. Mar Drugs 2020; 18:657. [PMID: 33371188 PMCID: PMC7767343 DOI: 10.3390/md18120657] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2020] [Revised: 12/05/2020] [Accepted: 12/07/2020] [Indexed: 12/22/2022] Open
Abstract
The natural products of heterobranch molluscs display a huge variability both in structure and in their bioactivity. Despite the considerable lack of information, it can be observed from the recent literature that this group of animals possesses an astonishing arsenal of molecules from different origins that provide the molluscs with potent chemicals that are ecologically and pharmacologically relevant. In this review, we analyze the bioactivity of more than 450 compounds from ca. 400 species of heterobranch molluscs that are useful for the snails to protect themselves in different ways and/or that may be useful to us because of their pharmacological activities. Their ecological activities include predator avoidance, toxicity, antimicrobials, antifouling, trail-following and alarm pheromones, sunscreens and UV protection, tissue regeneration, and others. The most studied ecological activity is predation avoidance, followed by toxicity. Their pharmacological activities consist of cytotoxicity and antitumoral activity; antibiotic, antiparasitic, antiviral, and anti-inflammatory activity; and activity against neurodegenerative diseases and others. The most studied pharmacological activities are cytotoxicity and anticancer activities, followed by antibiotic activity. Overall, it can be observed that heterobranch molluscs are extremely interesting in regard to the study of marine natural products in terms of both chemical ecology and biotechnology studies, providing many leads for further detailed research in these fields in the near future.
Collapse
Affiliation(s)
- Conxita Avila
- Department of Evolutionary Biology, Ecology, and Environmental Sciences, Biodiversity Research Institute (IrBIO), Faculty of Biology, University of Barcelona, Av. Diagonal 643, 08028 Barcelona, Catalonia, Spain;
| | - Carlos Angulo-Preckler
- Department of Evolutionary Biology, Ecology, and Environmental Sciences, Biodiversity Research Institute (IrBIO), Faculty of Biology, University of Barcelona, Av. Diagonal 643, 08028 Barcelona, Catalonia, Spain;
- Norwegian College of Fishery Science, UiT The Arctic University of Norway, Hansine Hansens veg 18, 9019 Tromsø, Norway
| |
Collapse
|
2
|
Váradi T, Schneider M, Sevcsik E, Kiesenhofer D, Baumgart F, Batta G, Kovács T, Platzer R, Huppa JB, Szöllősi J, Schütz GJ, Brameshuber M, Nagy P. Homo- and Heteroassociations Drive Activation of ErbB3. Biophys J 2019; 117:1935-1947. [PMID: 31653451 PMCID: PMC7018998 DOI: 10.1016/j.bpj.2019.10.001] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2019] [Revised: 10/01/2019] [Accepted: 10/03/2019] [Indexed: 01/19/2023] Open
Abstract
Dimerization or the formation of higher-order oligomers is required for the activation of ErbB receptor tyrosine kinases. The heregulin (HRG) receptor, ErbB3, must heterodimerize with other members of the family, preferentially ErbB2, to form a functional signal transducing complex. Here, we applied single molecule imaging capable of detecting long-lived and mobile associations to measure their stoichiometry and mobility and analyzed data from experiments globally, taking the different lateral mobility of monomeric and dimeric molecular species into account. Although ErbB3 was largely monomeric in the absence of stimulation and ErbB2 co-expression, a small fraction was present as constitutive homodimers exhibiting a ∼40% lower mobility than monomers. HRG stimulation increased the homodimeric fraction of ErbB3 significantly and reduced the mobility of homodimers fourfold compared to constitutive homodimers. Expression of ErbB2 elevated the homodimeric fraction of ErbB3 even in unstimulated cells and induced a ∼2-fold reduction in the lateral mobility of ErbB3 homodimers. The mobility of ErbB2 was significantly lower than that of ErbB3, and HRG induced a less pronounced decrease in the diffusion coefficient of all ErbB2 molecules and ErbB3/ErbB2 heterodimers than in the mobility of ErbB3. The slower diffusion of ErbB2 compared to ErbB3 was abolished by depolymerizing actin filaments, whereas ErbB2 expression induced a substantial rearrangement of microfilaments, implying a bidirectional interaction between ErbB2 and actin. HRG stimulation of cells co-expressing ErbB3 and ErbB2 led to the formation of ErbB3 homodimers and ErbB3/ErbB2 heterodimers in a competitive fashion. Although pertuzumab, an antibody binding to the dimerization arm of ErbB2, completely abolished the formation of constitutive and HRG-induced ErbB3/ErbB2 heterodimers, it only slightly blocked ErbB3 homodimerization. The results imply that a dynamic equilibrium exists between constitutive and ligand-induced homo- and heterodimers capable of shaping transmembrane signaling.
Collapse
Affiliation(s)
- Tímea Váradi
- Institute of Applied Physics, TU Wien, Vienna, Austria; Department of Biophysics and Cell Biology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
| | | | - Eva Sevcsik
- Institute of Applied Physics, TU Wien, Vienna, Austria
| | | | | | - Gyula Batta
- Department of Biophysics and Cell Biology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary; Department of Genetics and Applied Microbiology, Faculty of Science of Technology, University of Debrecen, Debrecen, Hungary
| | - Tamás Kovács
- Institute of Applied Physics, TU Wien, Vienna, Austria
| | - René Platzer
- Institute for Hygiene and Applied Immunology, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
| | - Johannes B Huppa
- Institute for Hygiene and Applied Immunology, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
| | - János Szöllősi
- Department of Biophysics and Cell Biology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary; MTA-DE Cell Biology and Signaling Research Group, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
| | | | | | - Peter Nagy
- Department of Biophysics and Cell Biology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
| |
Collapse
|
3
|
Liu S, Shen Z, Wu B, Yu Y, Hou H, Zhang XX, Ren HQ. Cytotoxicity and Efflux Pump Inhibition Induced by Molybdenum Disulfide and Boron Nitride Nanomaterials with Sheetlike Structure. ENVIRONMENTAL SCIENCE & TECHNOLOGY 2017; 51:10834-10842. [PMID: 28841301 DOI: 10.1021/acs.est.7b02463] [Citation(s) in RCA: 44] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
Sheetlike molybdenum disulfide (MoS2) and boron nitride (BN) nanomaterials have attracted attention in the past few years due to their unique material properties. However, information on adverse effects and their underlying mechanisms for sheetlike MoS2 and BN nanomaterials is rare. In this study, cytotoxicities of sheetlike MoS2 and BN nanomaterials on human hepatoma HepG2 cells were systematically investigated at different toxic end points. Results showed that MoS2 and BN nanomaterials decreased cell viability at 30 μg/mL and induced adverse effects on intracellular ROS generation (≥2 μg/mL), mitochondrial depolarization (≥4 μg/mL), and membrane integrity (≥8 μg/mL for MoS2 and ≥2 μg/mL for BN). Furthermore, this study first found that low exposure concentrations (0.2-2 μg/mL) of MoS2 and BN nanomaterials could increase plasma membrane fluidity and inhibit transmembrane ATP binding cassette (ABC) efflux transporter activity, which make both nanomaterials act as a chemosensitizer (increasing arsenic toxicity). Damage to plasma membrane and release of soluble Mo or B species might be two reasons that both nanomaterials inhibit efflux pump activities. This study provides a systematic understanding of the cytotoxicity of sheetlike MoS2 and BN nanomaterials at different exposure levels, which is important for their safe use.
Collapse
Affiliation(s)
- Su Liu
- State Key Laboratory of Pollution Control and Resource Reuse, School of the Environment, Nanjing University , Nanjing, 210023, P. R. China
| | - Zhuoyan Shen
- State Key Laboratory of Pollution Control and Resource Reuse, School of the Environment, Nanjing University , Nanjing, 210023, P. R. China
| | - Bing Wu
- State Key Laboratory of Pollution Control and Resource Reuse, School of the Environment, Nanjing University , Nanjing, 210023, P. R. China
| | - Yue Yu
- State Key Laboratory of Pollution Control and Resource Reuse, School of the Environment, Nanjing University , Nanjing, 210023, P. R. China
| | - Hui Hou
- State Key Laboratory of Pollution Control and Resource Reuse, School of the Environment, Nanjing University , Nanjing, 210023, P. R. China
| | - Xu-Xiang Zhang
- State Key Laboratory of Pollution Control and Resource Reuse, School of the Environment, Nanjing University , Nanjing, 210023, P. R. China
| | - Hong-Qiang Ren
- State Key Laboratory of Pollution Control and Resource Reuse, School of the Environment, Nanjing University , Nanjing, 210023, P. R. China
| |
Collapse
|
4
|
Ciavatta ML, Lefranc F, Carbone M, Mollo E, Gavagnin M, Betancourt T, Dasari R, Kornienko A, Kiss R. Marine Mollusk-Derived Agents with Antiproliferative Activity as Promising Anticancer Agents to Overcome Chemotherapy Resistance. Med Res Rev 2017; 37:702-801. [PMID: 27925266 PMCID: PMC5484305 DOI: 10.1002/med.21423] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2016] [Revised: 09/20/2016] [Accepted: 09/23/2016] [Indexed: 12/18/2022]
Abstract
The chemical investigation of marine mollusks has led to the isolation of a wide variety of bioactive metabolites, which evolved in marine organisms as favorable adaptations to survive in different environments. Most of them are derived from food sources, but they can be also biosynthesized de novo by the mollusks themselves, or produced by symbionts. Consequently, the isolated compounds cannot be strictly considered as "chemotaxonomic markers" for the different molluscan species. However, the chemical investigation of this phylum has provided many compounds of interest as potential anticancer drugs that assume particular importance in the light of the growing literature on cancer biology and chemotherapy. The current review highlights the diversity of chemical structures, mechanisms of action, and, most importantly, the potential of mollusk-derived metabolites as anticancer agents, including those biosynthesized by mollusks and those of dietary origin. After the discussion of dolastatins and kahalalides, compounds previously studied in clinical trials, the review covers potentially promising anticancer agents, which are grouped based on their structural type and include terpenes, steroids, peptides, polyketides and nitrogen-containing compounds. The "promise" of a mollusk-derived natural product as an anticancer agent is evaluated on the basis of its ability to target biological characteristics of cancer cells responsible for poor treatment outcomes. These characteristics include high antiproliferative potency against cancer cells in vitro, preferential inhibition of the proliferation of cancer cells over normal ones, mechanism of action via nonapoptotic signaling pathways, circumvention of multidrug resistance phenotype, and high activity in vivo, among others. The review also includes sections on the targeted delivery of mollusk-derived anticancer agents and solutions to their procurement in quantity.
Collapse
Affiliation(s)
- Maria Letizia Ciavatta
- Consiglio Nazionale delle Ricerche (CNR)Istituto di Chimica Biomolecolare (ICB)Via Campi Flegrei 3480078PozzuoliItaly
| | - Florence Lefranc
- Service de Neurochirurgie, Hôpital ErasmeUniversité Libre de Bruxelles (ULB)1070BrusselsBelgium
| | - Marianna Carbone
- Consiglio Nazionale delle Ricerche (CNR)Istituto di Chimica Biomolecolare (ICB)Via Campi Flegrei 3480078PozzuoliItaly
| | - Ernesto Mollo
- Consiglio Nazionale delle Ricerche (CNR)Istituto di Chimica Biomolecolare (ICB)Via Campi Flegrei 3480078PozzuoliItaly
| | - Margherita Gavagnin
- Consiglio Nazionale delle Ricerche (CNR)Istituto di Chimica Biomolecolare (ICB)Via Campi Flegrei 3480078PozzuoliItaly
| | - Tania Betancourt
- Department of Chemistry and BiochemistryTexas State UniversitySan MarcosTX78666
| | - Ramesh Dasari
- Department of Chemistry and BiochemistryTexas State UniversitySan MarcosTX78666
| | - Alexander Kornienko
- Department of Chemistry and BiochemistryTexas State UniversitySan MarcosTX78666
| | - Robert Kiss
- Laboratoire de Cancérologie et de Toxicologie ExpérimentaleFaculté de Pharmacie, Université Libre de Bruxelles (ULB)1050BrusselsBelgium
| |
Collapse
|
5
|
Liu S, Jiang W, Wu B, Yu J, Yu H, Zhang XX, Torres-Duarte C, Cherr GN. Low levels of graphene and graphene oxide inhibit cellular xenobiotic defense system mediated by efflux transporters. Nanotoxicology 2015; 10:597-606. [DOI: 10.3109/17435390.2015.1104739] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
6
|
Abstract
Cyclic depsipeptides are polypeptides in which one or more amino acid is replaced by a hydroxy acid, resulting in the formation of at least one ester bond in the core ring structure. Many natural cyclic depsipeptides possessing intriguing structural and biological properties, including antitumor, antifungal, antiviral, antibacterial, anthelmintic, and anti-inflammatory activities, have been identified from fungi, plants, and marine organisms. In particular, the potent effects of cyclic depsipeptides on tumor cells have led to a number of clinical trials evaluating their potential as chemotherapeutic agents. Although many of the trials have not achieved the desired results, romidepsin (FK228), a bicyclic depsipeptide that inhibits histone deacetylase, has been shown to have clinical efficacy in patients with refractory cutaneous T-cell lymphoma and has received Food and Drug Administration approval for use in treatment. In this review, we discuss antitumor cyclic depsipeptides that have undergone clinical trials and focus on their structural features, mechanisms, potential applications in chemotherapy, and pharmacokinetic and toxicity data. The results of this study indicate that cyclic depsipeptides could be a rich source of new cancer therapeutics.
Collapse
|
7
|
Molina-Guijarro JM, García C, Macías Á, García-Fernández LF, Moreno C, Reyes F, Martínez-Leal JF, Fernández R, Martínez V, Valenzuela C, Lillo MP, Galmarini CM. Elisidepsin Interacts Directly with Glycosylceramides in the Plasma Membrane of Tumor Cells to Induce Necrotic Cell Death. PLoS One 2015; 10:e0140782. [PMID: 26474061 PMCID: PMC4608773 DOI: 10.1371/journal.pone.0140782] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2015] [Accepted: 09/30/2015] [Indexed: 12/31/2022] Open
Abstract
Plasma membrane integrity is essential for cell life. Any major break on it immediately induces the death of the affected cell. Different molecules were described as disrupting this cell structure and thus showing antitumor activity. We have previously defined that elisidepsin (Irvalec®, PM02734) inserts and self-organizes in the plasma membrane of tumor cells, inducing a rapid loss of membrane integrity, cell permeabilization and necrotic death. Here we show that, in sensitive HCT-116 colorectal cells, all these effects are consequence of the interaction of elisidepsin with glycosylceramides in the cell membrane. Of note, an elisidepsin-resistant subline (HCT-116-Irv) presented reduced levels of glycosylceramides and no accumulation of elisidepsin in the plasma membrane. Consequently, drug treatment did not induce the characteristic necrotic cell death. Furthermore, GM95, a mutant derivative from B16 mouse melanoma cells lacking ceramide glucosyltransferase (UGCG) activity and thus the synthesis of glycosylceramides, was also resistant to elisidepsin. Over-expression of UGCG gene in these deficient cells restored glycosylceramides synthesis, rendering them sensitive to elisidepsin, at a similar level than parental B16 cells. These results indicate that glycosylceramides act as membrane targets of elisidepsin, facilitating its insertion in the plasma membrane and the subsequent membrane permeabilization that leads to drug-induced cell death. They also indicate that cell membrane lipids are a plausible target for antineoplastic therapy.
Collapse
Affiliation(s)
| | - Carolina García
- Departamento de Química Física Biológica, Instituto de Química-Física “Rocasolano” (CSIC), Madrid, Spain
| | - Álvaro Macías
- Instituto de Investigaciones Biomédicas “Alberto Sols” (CSIC-UAM), Madrid, Spain
| | | | - Cristina Moreno
- Instituto de Investigaciones Biomédicas “Alberto Sols” (CSIC-UAM), Madrid, Spain
| | - Fernando Reyes
- Fundación MEDINA, Parque Tecnológico de Ciencias de la Salud, Armilla, Granada, Spain
| | | | - Rogelio Fernández
- Departamento de Investigación y Desarrollo, PharmaMar S.A., Colmenar Viejo, Madrid, Spain
| | - Valentín Martínez
- Departamento de Investigación y Desarrollo, PharmaMar S.A., Colmenar Viejo, Madrid, Spain
| | - Carmen Valenzuela
- Instituto de Investigaciones Biomédicas “Alberto Sols” (CSIC-UAM), Madrid, Spain
| | - M. Pilar Lillo
- Departamento de Química Física Biológica, Instituto de Química-Física “Rocasolano” (CSIC), Madrid, Spain
| | - Carlos M. Galmarini
- Departamento de Investigación y Desarrollo, PharmaMar S.A., Colmenar Viejo, Madrid, Spain
| |
Collapse
|
8
|
McNeill SM, Preston D, Lewis JEM, Robert A, Knerr-Rupp K, Graham DO, Wright JR, Giles GI, Crowley JD. Biologically active [Pd2L4](4+) quadruply-stranded helicates: stability and cytotoxicity. Dalton Trans 2015; 44:11129-36. [PMID: 25997516 DOI: 10.1039/c5dt01259g] [Citation(s) in RCA: 71] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
There is emerging interest in the anti-proliferative effects of metallosupramolecular systems due to the different size and shape of these metallo-architectures compared to traditional small molecule drugs. Palladium(II)-containing systems are the most abundant class of metallosupramolecular complexes, yet their biological activity has hardly been examined. Here a small series of [Pd2(L)4](BF4)4 quadruply-stranded, dipalladium(II) architectures were screened for their cytotoxic effects against three cancer cell lines and one non-malignant line. The helicates exhibited a range of cytotoxic properties, with the most cytotoxic complex [Pd2(hextrz)4](BF4)4 possessing low micromolar IC50 values against all of the cell lines tested, while the other helicates displayed moderate or no cytotoxicity. Against the MDA-MB-231 cell line, which is resistant to platinum-based drugs, [Pd2(hextrz)4](BF4)4 was 7-fold more active than cisplatin. Preliminary mechanistic studies indicate that the [Pd2(hextrz)4](BF4)4 helicate does not induce cell death in the same way as clinically used metal complexes such as cisplatin. Rather than interacting with DNA, the helicate appears to disrupt the cell membrane. These studies represent the first biological characterisation of quadruply-stranded helicate architectures, and provide insight into the design requirements for the development of biologically active and stable palladium(II)-containing metallosupramolecular architectures.
Collapse
Affiliation(s)
- Samantha M McNeill
- Department of Pharmacology and Toxicology, University of Otago, P.O. Box 913, Dunedin, New Zealand.
| | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Ratain MJ, Geary D, Undevia SD, Coronado C, Alfaro V, Iglesias JL, Schilsky RL, Miguel-Lillo B. First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors. Invest New Drugs 2015; 33:901-10. [PMID: 25947566 DOI: 10.1007/s10637-015-0247-1] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2015] [Accepted: 04/29/2015] [Indexed: 11/26/2022]
Abstract
This first-in-human, phase I clinical trial was designed to determine the dose-limiting toxicities (DLTs) and the dose for phase II trials (P2D) of elisidepsin (PM02734) administered as a 30-min or as a 3-h intravenous infusion every 3 weeks (q3wk). Between March 2006 and April 2011, 53 patients with advanced malignant solid tumors were enrolled and treated with elisidepsin on the two different q3wk infusion schedules: 22 (30-min) and 31 (3-h), respectively. Doses evaluated ranged from 0.1 to 1.6 mg/m(2) (30-min q3wk) and from 2.0 to 11.0 mg flat dose (FD) (3-h q3wk). In the 30-min q3wk schedule, transient grade 3/4 increases in hepatic transaminases were the DLT, which appeared at the highest doses tested (from 1.1 to 1.6 mg/m(2)). No DLTs were observed on the 3-h schedule at doses up to 11.0 mg q3wk. Common adverse events were grade 1/2 pruritus, nausea, fatigue and hypersensitivity. Of note, myelotoxicity was not observed. Plasma maximum concentration and total drug exposure increased linearly with dose. Prolonged (≥3 months) disease stabilization was observed in pretreated patients with pleural mesothelioma (n = 1) in the 30-min q3wk arm, and with colorectal adenocarcinoma (n = 3), esophagus adenocarcinoma, endometrium adenocarcinoma, pleural mesothelioma, and head and neck carcinoma (n = 1 each) in the 3-h q3wk arm. In conclusion, elisidepsin doses of 1.1 mg/m(2) (equivalent to a FD of 2.0 mg) and 11.0 mg FD are the dose levels achieved for further phase II trials testing the 30-min q3wk and 3-h q3wk schedules, respectively.
Collapse
Affiliation(s)
- Mark J Ratain
- Department of Medicine, University of Chicago, MC2115, 5841 South Maryland Avenue, Chicago, IL, 60637, USA,
| | | | | | | | | | | | | | | |
Collapse
|
10
|
Király A, Váradi T, Hajdu T, Rühl R, Galmarini CM, Szöllősi J, Nagy P. Hypoxia reduces the efficiency of elisidepsin by inhibiting hydroxylation and altering the structure of lipid rafts. Mar Drugs 2013; 11:4858-75. [PMID: 24317474 PMCID: PMC3877891 DOI: 10.3390/md11124858] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2013] [Revised: 10/26/2013] [Accepted: 11/05/2013] [Indexed: 12/18/2022] Open
Abstract
The mechanism of action of elisidepsin (PM02734, Irvalec®) is assumed to involve membrane permeabilization via attacking lipid rafts and hydroxylated lipids. Here we investigate the role of hypoxia in the mechanism of action of elisidepsin. Culturing under hypoxic conditions increased the half-maximal inhibitory concentration and decreased the drug’s binding to almost all cell lines which was reversed by incubation of cells with 2-hydroxy palmitic acid. The expression of fatty acid 2-hydroxylase was strongly correlated with the efficiency of the drug and inversely correlated with the effect of hypoxia. Number and brightness analysis and fluorescence anisotropy experiments showed that hypoxia decreased the clustering of lipid rafts and altered the structure of the plasma membrane. Although the binding of elisidepsin to the membrane is non-cooperative, its membrane permeabilizing effect is characterized by a Hill coefficient of ~3.3. The latter finding is in agreement with elisidepsin-induced clusters of lipid raft-anchored GFP visualized by confocal microscopy. We propose that the concentration of elisidepsin needs to reach a critical level in the membrane above which elisidepsin induces the disruption of the cell membrane. Testing for tumor hypoxia or the density of hydroxylated lipids could be an interesting strategy to increase the efficiency of elisidepsin.
Collapse
Affiliation(s)
- Anna Király
- Department of Biophysics and Cell Biology, University of Debrecen, Nagyerdei krt. 98, Debrecen 4032, Hungary; E-Mails: (A.K.); (T.V.); (T.H.); (J.S.)
| | - Tímea Váradi
- Department of Biophysics and Cell Biology, University of Debrecen, Nagyerdei krt. 98, Debrecen 4032, Hungary; E-Mails: (A.K.); (T.V.); (T.H.); (J.S.)
| | - Tímea Hajdu
- Department of Biophysics and Cell Biology, University of Debrecen, Nagyerdei krt. 98, Debrecen 4032, Hungary; E-Mails: (A.K.); (T.V.); (T.H.); (J.S.)
| | - Ralph Rühl
- Department of Biochemistry and Molecular Biology, University of Debrecen, Nagyerdei krt. 98, Debrecen 4032, Hungary; E-Mail:
| | - Carlos M. Galmarini
- Cell Biology Department, PharmaMar, Avda de los Reyes 1, Pol. Ind. La Mina, Colmenar Viejo, Madrid 28770, Spain; E-Mail:
| | - János Szöllősi
- Department of Biophysics and Cell Biology, University of Debrecen, Nagyerdei krt. 98, Debrecen 4032, Hungary; E-Mails: (A.K.); (T.V.); (T.H.); (J.S.)
- MTA-DE Cell Biology and Signaling Research Group, University of Debrecen, Nagyerdei krt. 98, Debrecen 4032, Hungary
| | - Peter Nagy
- Department of Biophysics and Cell Biology, University of Debrecen, Nagyerdei krt. 98, Debrecen 4032, Hungary; E-Mails: (A.K.); (T.V.); (T.H.); (J.S.)
- Author to whom correspondence should be addressed; E-Mail: ; Tel.: +36-52-412-623; Fax: +36-52-532-201
| |
Collapse
|
11
|
Serova M, de Gramont A, Bieche I, Riveiro ME, Galmarini CM, Aracil M, Jimeno J, Faivre S, Raymond E. Predictive factors of sensitivity to elisidepsin, a novel Kahalalide F-derived marine compound. Mar Drugs 2013; 11:944-59. [PMID: 23519149 PMCID: PMC3705381 DOI: 10.3390/md11030944] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2012] [Revised: 01/21/2013] [Accepted: 02/22/2013] [Indexed: 01/20/2023] Open
Abstract
Elisidepsin (PM02734, Irvalec®) is a synthetic marine-derived cyclic peptide of the Kahalalide F family currently in phase II clinical development. Elisidepsin was shown to induce rapid oncosis in ErbB3-expressing cells. Other predictive factors of elisidepsin sensitivity remained unknown. A panel of 23 cancer cell lines of different origin was assessed for elisidepsin cytotoxicity and correlated with mutational state, mRNA and protein expression of selected genes. Elisidepsin showed potent and broad cytotoxic effects in our cancer cell line panel, being active at concentrations ranging from 0.4 to 2 μM that may be relevant for clinical settings. We have shown that elisidepsin is more active in cells harboring epithelial phenotype with high E-cadherin and low vimentin expression. In addition, high ErbB3 and Muc1 expression was correlated with sensitivity to elisidepsin, whereas the presence of KRAS activating mutations was associated with resistance. In DU-PM cells with acquired resistance to elisidepsin, ErbB3 expression was decreased, while Bcl2 was increased. DU-PM cells displayed higher sensitivity to ErbB1-inhibitors suggesting possible cross-talk of ErbB1 and ErbB3 signaling pathways. Combinations of elisidepsin with lapatinib and several chemotherapies including 5-FU and oxaliplatin resulted in synergistic effects that offer the potential of clinical use of elisidepsin in combination settings.
Collapse
Affiliation(s)
- Maria Serova
- AAREC Filia Research, 1, Paul Verlaine, Boulogne Billancourt 92100, France; E-Mails: (M.S.); (A.G.)
- INSERM U728 and Departments of Medical Oncology, Beaujon University Hospital (AP-HP-Paris 7 Diderot), 100, bd General Leclerc, Clichy 92110, France; E-Mails: (M.E.R.); (S.F.)
| | - Armand de Gramont
- AAREC Filia Research, 1, Paul Verlaine, Boulogne Billancourt 92100, France; E-Mails: (M.S.); (A.G.)
- INSERM U728 and Departments of Medical Oncology, Beaujon University Hospital (AP-HP-Paris 7 Diderot), 100, bd General Leclerc, Clichy 92110, France; E-Mails: (M.E.R.); (S.F.)
| | - Ivan Bieche
- Laboratory of Molecular Genetics, Beaujon University Hospital, Paris 7 Diderot, 100, bd General Leclerc, Clichy 92110, France; E-Mail:
| | - Maria Eugenia Riveiro
- INSERM U728 and Departments of Medical Oncology, Beaujon University Hospital (AP-HP-Paris 7 Diderot), 100, bd General Leclerc, Clichy 92110, France; E-Mails: (M.E.R.); (S.F.)
| | - Carlos Maria Galmarini
- Cell Biology Department, PharmaMar, Avda de los Reyes 1, Pol. Ind. La Mina, Colmenar Viejo (Madrid) 28770, Spain; E-Mails: (C.M.G.); (M.A.); (J.J.)
| | - Miguel Aracil
- Cell Biology Department, PharmaMar, Avda de los Reyes 1, Pol. Ind. La Mina, Colmenar Viejo (Madrid) 28770, Spain; E-Mails: (C.M.G.); (M.A.); (J.J.)
| | - José Jimeno
- Cell Biology Department, PharmaMar, Avda de los Reyes 1, Pol. Ind. La Mina, Colmenar Viejo (Madrid) 28770, Spain; E-Mails: (C.M.G.); (M.A.); (J.J.)
| | - Sandrine Faivre
- INSERM U728 and Departments of Medical Oncology, Beaujon University Hospital (AP-HP-Paris 7 Diderot), 100, bd General Leclerc, Clichy 92110, France; E-Mails: (M.E.R.); (S.F.)
| | - Eric Raymond
- INSERM U728 and Departments of Medical Oncology, Beaujon University Hospital (AP-HP-Paris 7 Diderot), 100, bd General Leclerc, Clichy 92110, France; E-Mails: (M.E.R.); (S.F.)
- Author to whom correspondence should be addressed; E-Mail: ; Tel.: +33-1-4087-5614; Fax: +33-1-4087-5487
| |
Collapse
|
12
|
Teixidó C, Marés R, Aracil M, Ramón y Cajal S, Hernández-Losa J. Epithelial-mesenchymal transition markers and HER3 expression are predictors of elisidepsin treatment response in breast and pancreatic cancer cell lines. PLoS One 2013; 8:e53645. [PMID: 23320098 PMCID: PMC3539985 DOI: 10.1371/journal.pone.0053645] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2012] [Accepted: 12/03/2012] [Indexed: 12/23/2022] Open
Abstract
Elisidepsin (elisidepsin trifluoroacetate, Irvalec®, PM02734) is a new synthetic depsipeptide, a result of the PharmaMar Development Program that seeks synthetic products of marine origin-derived compounds. Elisidepsin is a drug with antiproliferative activity in a wide range of tumors. In the present work we studied and characterized the mechanisms associated with sensitivity and resistance to elisidepsin treatment in a broad panel of tumor cell lines from breast and pancreas carcinomas, focusing on different factors involved in epithelial-mesenchymal transition (EMT) and the use of HER family receptors in predicting the in vitro drug response. Interestingly, we observed that the basal protein expression levels of EMT markers show a significant correlation with cell viability in response to elisidepsin treatment in a panel of 12 different breast and pancreatic cancer cell lines. In addition, we generated three elisidepsin treatment-resistant cell lines (MCF-7, HPAC and AsPC-1) and analyzed the pattern of expression of different EMT markers in these cells, confirming that acquired resistance to elisidepsin is associated with a switch to the EMT state. Furthermore, a direct correlation between basal HER3 expression and sensitivity to elisidepsin was observed; moreover, modulation of HER3 expression levels in different cancer cell lines alter their sensitivities to the drug, making them more resistant when HER3 expression is downregulated by a HER3-specific short hairpin RNA and more sensitive when the receptor is overexpressed. These results show that HER3 expression is an important marker of sensitivity to elisidepsin treatment.
Collapse
Affiliation(s)
- Cristina Teixidó
- Molecular Pathology Group, Vall d’Hebron Research Institute, Universidad Autonoma of Barcelona, Barcelona, Spain
| | - Rosó Marés
- Molecular Pathology Group, Vall d’Hebron Research Institute, Universidad Autonoma of Barcelona, Barcelona, Spain
| | | | - Santiago Ramón y Cajal
- Pathology Department, Vall d’Hebron University Hospital, Universidad Autonoma of Barcelona, Barcelona, Spain
| | - Javier Hernández-Losa
- Pathology Department, Vall d’Hebron University Hospital, Universidad Autonoma of Barcelona, Barcelona, Spain
| |
Collapse
|